Possible roles of cardiac chymase after myocardial infarction in hamster hearts

D Jin1, S Takai, M Yamada

  • 1Department of Pharmacology, Osaka Medical College, Takatsuki City, Japan.

Insights

Cardiac chymase activity significantly increases after myocardial infarction (MI) in hamsters. Angiotensin II receptor blockade improved survival and hemodynamics, suggesting chymase-derived Ang II contributes to post-MI pathology.

Area of Science:

  • Cardiovascular Research
  • Enzymology
  • Pharmacology

Background:

  • Myocardial infarction (MI) triggers complex cardiac remodeling processes.
  • Cardiac chymase and angiotensin-converting enzyme (ACE) are implicated in cardiovascular disease.
  • The specific role of cardiac chymase in post-MI pathophysiology remains to be fully elucidated.

Purpose of the Study:

  • To evaluate the significance of cardiac chymase after myocardial infarction (MI) in a hamster model.
  • To investigate the temporal changes in cardiac chymase and ACE activities post-MI.
  • To assess the therapeutic effects of an angiotensin II receptor antagonist versus an ACE inhibitor on post-MI outcomes.

Main Methods:

  • A hamster model of MI was established using left coronary artery ligation.
  • Cardiac tissues were analyzed for chymase and ACE activities at various time points post-MI.
  • Plasma renin activity and hemodynamic parameters were measured.
  • Animals were treated with candesartan cilexetil (Ang II receptor antagonist) or lisinopril (ACE inhibitor) before and after MI.

Main Results:

  • MI led to increased left ventricle weight and infarct size.
  • Plasma renin activity increased early post-MI; cardiac ACE activity increased from day 3 to 28.
  • Cardiac chymase activity and chymase-positive mast cells significantly increased from day 1 to 56 post-MI.
  • Candesartan cilexetil reduced mortality and improved hemodynamics, while lisinopril did not show significant benefits.

Conclusions:

  • Cardiac chymase activity is significantly upregulated following MI in hamsters.
  • Chymase-derived angiotensin II may play a crucial role in the adverse pathophysiological changes after MI.
  • Targeting the angiotensin II type 1 receptor with candesartan cilexetil offers therapeutic potential post-MI.

Related Concept Videos